PainCeptor Pharma
Saint-laurent, Manitoba, Canada
About PainCeptor Pharma
PainCeptor Pharma is a pharmaceutical company developing next generation therapeutic drugs for the treatment of chronic and acute pain. PainCeptor's therapeutic programs are concentrated on some of the most promising, novel, yet scientifically validated therapeutic targets within the PNS (peripheral nervous system). By focusing on modulating target receptors in the PNS, PainCeptor expects to enhance the efficacy and avoid the many detrimental side effects associated with today's pain drugs which act primarily in the CNS (central nervous system). PainCeptor's development pipeline includes two lead antagonist programs, targeting NGF/p75-TrkA and ASIC1a, and a third antagonist program targeting ASIC3.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $37.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2007)
- Website: painceptor.com
- Phone: +1 514 337-5959
Industries & Categories
Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/painceptor-pharma-2520001 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.